

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/999179/uwe-fuhr-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122 papers	4,146 citations	33 h-index	61 g-index
129 ext. papers	4,617 ext. citations	4.7 avg, IF	5.28 L-index

#	Paper	IF	Citations
122	Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups.. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2022</b> ,	4.5	2
121	Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors.. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2022</b> , 1	3.5	
120	Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. <i>BMC Cancer</i> , <b>2021</b> , 21, 719	4.8	1
119	A Model-Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 1240-1249	6.1	0
118	Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 825-827	5.1	19
117	Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1495-1508	6.2	0
116	Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 365-374	6.5	0
115	A Population Pharmacokinetic Model of (R)- and (S)- Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61, 961-971	2.9	2
114	A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 1237-1253	2.9	1
113	Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , <b>2020</b> , 9, 4991-5007	4.8	9
112	Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 711-722	3.5	3
111	Frequency and Types of Pathological Upper Gastrointestinal Endoscopy Findings in Clinically Healthy Individuals. <i>Drugs in R and D</i> , <b>2020</b> , 20, 115-124	3.4	
110	Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics. <i>Neurocritical Care</i> , <b>2020</b> , 33, 740-748	3.3	3
109	Reporting the details of consent procedures in clinical trials. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 117, 150-151	5.7	1
108	A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 781-808	6.2	17
107	The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitro. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 1481-1482	2.8	1
106	Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. <i>Scientific Reports</i> , <b>2020</b> , 10, 12457	4.9	6

105	A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 518	5.6	3
104	A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2019</b> , 392, 1097-1106	3.4	4
103	A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2019</b> , 175, 112754	3.5	5
102	Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2019</b> , 1125, 121718	3.2	3
101	A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 1398-1407	6.1	14
100	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 643-657	2.6	31
99	Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2019</b> , 59, 507-536	17.9	22
98	Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 682-690	5.1	6
97	Response to "Impact of Acute Alcohol Exposure on P-Glycoprotein Function at the Blood-Brain Barrier Assessed Using C-Metoclopramide PET Imaging". <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 814	6.1	3
96	Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 104, 1249-1259	6.1	15
95	Pharmacokinetic Phenotyping to Predict Drug-Drug Interactions: Time to Divorce the Hybrid Concept of Simultaneous Mechanistic-Based and Exposure-Based Assessment. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 42	6.1	3
94	Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples. <i>Pharmacology</i> , <b>2018</b> , 101, 29-34	2.3	4
93	Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects. <i>Pharmacology</i> , <b>2018</b> , 102, 133-137	2.3	2
92	Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2304-2310	5.1	14
91	Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. <i>Therapeutic Advances in Urology</i> , <b>2017</b> , 9, 163-177	3.2	1
90	Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5254-61	5.9	27
89	Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples. <i>Pharmacology</i> , <b>2016</b> , 98, 70-2	2.3	1
88	Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2016</b> , 77, 66-75	1.7	13

87	Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 84-92	8.9	10
86	Adverse events during placebo vs. no drug administration--results of a randomised interventional trial in 160 volunteers. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1403-5	2.8	1
85	A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. <i>AAPS Journal</i> , <b>2015</b> , 17, 1483-91	3.7	7
84	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 38458-68	3.3	13
83	Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. <i>Breast Care</i> , <b>2014</b> , 9, 169-74	2.4	8
82	A novel toxicokinetic modeling of cypermethrin and permethrin and their metabolites in humans for dose reconstruction from biomarker data. <i>PLoS ONE</i> , <b>2014</b> , 9, e88517	3.7	21
81	Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 1162-9	2.9	16
80	Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1303-10	2.8	14
79	The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro. <i>Toxicology Mechanisms and Methods</i> , <b>2013</b> , 23, 576-83	3.6	6
78	Modeling NSCLC progression: recent advances and opportunities available. <i>AAPS Journal</i> , <b>2013</b> , 15, 542-59	3.7	11
77	Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 897-906	6.2	27
76	Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 359-71	6.2	4
75	Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 749-63	3.5	26
74	A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 763-81	6.2	27
73	Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 987-93	4	40
72	The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro. <i>Toxicology Mechanisms and Methods</i> , <b>2013</b> , 23, 346-51	3.6	6
71	Clinical impact of fluvoxamine-mediated long QTU syndrome. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 109-11	2.8	6
70	Natriuretic peptides in therapy for decompensated heart failure. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 223-30	2.8	22

69	Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps. <i>Molecular Nutrition and Food Research</i> , <b>2012</b> , 56, 1825-37	5.9	53
68	Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2012</b> , 70, 485-91	3.5	5
67	Effect of Ginkgo biloba special extract EGb 761 <sup>®</sup> on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 553-60	2.8	69
66	Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome p450 enzymes. <i>Planta Medica</i> , <b>2012</b> , 78, 1428-57	3.1	12
65	Study on the dosing accuracy of commonly used disposable insulin pens. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 804-9	8.1	20
64	Phenotyping the activity of drug metabolizing enzymes using limited sampling strategies: perturbations and bias. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 50, 476-7	2	1
63	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 371-403	6.2	80
62	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 551-603	6.2	137
61	Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 1831-41	3.5	20
60	Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 333-346	2.8	35
59	Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 927-32	4	31
58	Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. <i>European Journal of Endocrinology</i> , <b>2010</b> , 162, 1051-8	6.5	17
57	Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 370-2	2.9	2
56	Absorption, pharmacokinetics, and safety of triclosan after dermal administration. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 570-2	5.9	67
55	Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. <i>European Journal of Endocrinology</i> , <b>2010</b> , 163, 919-24	6.5	57
54	CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 43-53	2.6	51
53	Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 975-83	1.6	29
52	Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 1173-5	2.8	11

51	In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 433-43	4	52
50	Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2892-901	5.9	15
49	Mesalazine pharmacokinetics and NAT2 phenotype. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 47-54	2.8	9
48	Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 97-100	2.8	14
47	Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 19-31	2.8	142
46	Influence of posture on pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 109-19	2.8	31
45	Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 411-7	2.8	12
44	Clinical pharmacokinetics and pharmacodynamics of solifenacin. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 281-292	3.8	38
43	Pharmacogenetics of oral anticoagulants: a basis for dose individualization. <i>Clinical Pharmacokinetics</i> , <b>2008</b> , 47, 565-94	6.2	81
42	Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 387-98	2.8	6
41	Improvement in the handling of drug-drug interactions. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 167-71	2.8	18
40	Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 521-9	2.8	6
39	Professor Dr. Nina Bakracheva. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 835-6	2.8	
38	Influence of Genetic Polymorphisms of VKORC1 and CYP2C9 in Patients on Phenprocoumon Steady-State Dose Requirements. <i>Blood</i> , <b>2008</b> , 112, 4051-4051	2.2	
37	Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. <i>Clinical Pharmacokinetics</i> , <b>2007</b> , 46, 319-33	6.2	14
36	Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 270-83	6.1	184
35	The effect of silymarin on oral nifedipine pharmacokinetics. <i>Planta Medica</i> , <b>2007</b> , 73, 1429-35	3.1	42
34	Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 659-68	6.1	22



33	Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 266-71	4	111
32	Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 657-67	6.1	98
31	How may anticancer chemotherapy with fluorouracil be individualised?. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 567-92	6.2	37
30	Clinical pharmacokinetics of trospium chloride. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 701-20	6.2	68
29	The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 78, 441-3	6.1	4
28	Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?. <i>Nature Reviews Drug Discovery</i> , <b>2005</b> , 4, 639-47	64.1	127
27	Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 1733-8	5.9	157
26	Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 43, 573-4	2	1
25	Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. <i>European Journal of Clinical Pharmacology</i> , <b>2004</b> , 60, 17-21	2.8	16
24	Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. <i>European Journal of Clinical Pharmacology</i> , <b>2004</b> , 60, 165-71	2.8	65
23	Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , <b>2004</b> , 18, 1472-8	2.2	30
22	Quantification of mephenytoin and its metabolites 4-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method. <i>Rapid Communications in Mass Spectrometry</i> , <b>2004</b> , 18, 1675-80	2.2	8
21	Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 178-84	6.1	153
20	Detection of a novel 1905C-->T mutation within the dihydropyrimidine dehydrogenase gene and potential for misclassification with the exon 14-skipping mutation. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 707-8	5.5	1
19	An amperometric biosensor with human CYP3A4 as a novel drug screening tool. <i>Biochemical Pharmacology</i> , <b>2003</b> , 65, 1817-26	6	149
18	Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. <i>Biochemical Pharmacology</i> , <b>2002</b> , 63, 2159-67	6	17
17	Effects of grapefruit juice and smoking on verapamil concentrations in steady state. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 45-53	2.8	73
16	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2002</b> , 90, 144-9		25

15	Affinities of dihydrocodeine and its metabolites to opioid receptors. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2002</b> , 91, 57-63		32
14	Effects of grapefruit juice on the pharmacokinetics of sildenafil. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 21-9	6.1	64
13	Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2000</b> , 86, 250-6		102
12	Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. <i>Clinical Pharmacokinetics</i> , <b>2000</b> , 38, 493-504	6.2	106
11	Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1999</b> , 85, 299-304		31
10	Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 65, 262-74	6.1	32
9	Drug metabolism biosensors: electrochemical reactivities of cytochrome P450cam immobilised in synthetic vesicular systems. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>1998</b> , 17, 1101-10	3.5	64
8	Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. <i>Drug Safety</i> , <b>1998</b> , 18, 251-72	5.1	171
7	Absence of effect of rifloxacin on theophylline pharmacokinetics in steady state. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1998</b> , 42, 2359-64	5.9	8
6	Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. <i>Pharmacogenetics and Genomics</i> , <b>1996</b> , 6, 159-76		108
5	The fate of naringin in humans: a key to grapefruit juice-drug interactions?. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 58, 365-73	6.1	198
4	Study of coumarin metabolism by human liver microsomes using capillary electrophoresis. <i>Analytica Chimica Acta</i> , <b>1995</b> , 310, 101-107	6.6	16
3	Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. <i>Pharmacogenetics and Genomics</i> , <b>1994</b> , 4, 109-16		152
2	Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolones. <i>Toxicology</i> , <b>1993</b> , 82, 169-89	4.4	20
1	Theophylline metabolism affected by mexiletine. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 52, 107-9	6.1	0